Sacral Nerve Stimulation Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 5.50 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Sacral Nerve Stimulation Market Analysis
The Sacral Nerve Stimulation Market is expected to register a CAGR of 5.5% over the forecast period (2022-2027).
The impact of the COVID-19 outbreak on the sacral nerve stimulation market is expected to be significant, as most non-COVID treatment services were disrupted to reserve the healthcare infrastructure for COVID-19-infected patients and minimize the risk of transmission of the SARS-CoV-2 virus. According to a study published in the British Journal of Surgery in May 2020, due to 12 weeks of peak disruption in hospital services due to COVID-19, around 28.4 million elective surgeries worldwide were canceled or postponed and reviews suggest that between 16% to 20% of these surgical procedures constitute of sacral nerve surgical procedures, impacting the sacral nerve stimulation market. Additionally, according to a research study by Jeremy Yuen-Chun Teoh et al., titled " A Global Survey on the Impact of COVID-19 on Urological Services" (2020), globally, the outpatient clinics for female urinary incontinence, benign prostatic hyperplasia, infertility, and sexual medicine, benign scrotal conditions, renal stone, and bladder stone were the most affected by the pandemic. Also, a delay of more than eight weeks for urological services was reported for 28% of all outpatient clinics, 30% of all outpatient investigations and procedures, and 31% of all urological surgeries during the COVID-19 pandemic. Hence, given the facts, the studied market is predicted to be negatively impacted due to the COVID-19 pandemic.
The rising prevalence of overactive bladder conditions and the increasing incidence of urge incontinence, such as urinary tract infection (UTI), are the major drivers for the growth of the market studied. Also, the growing incidence of fecal incontinence and the availability of medical reimbursements are some other factors fueling the market growth. For instance, in 2021, an article titled, 'Epidemiological trends of urinary tract infections, urolithiasis and benign prostatic hyperplasia in 203 countries and territories' reported that globally, urinary tract infection (UTI) was attributed to the most disability-adjusted life-years (DALYs) among the three diseases reported in the article and about 68.89% of individuals were infected with urinary tract infections (UTI) globally during the study period.
Furthermore, the prevalence of urinary incontinence is more in women than in men. For instance, according to a research study by Sedighe Batman et al., published in the BMC Geriatrics Journal in March 2021, the highest prevalence of urinary incontinence was reported to be in older adult women in Asia (45.1%). Some factors influencing the incidence of urinary incontinence in older women are age, obesity, diabetes, hypertension, and smoking. Thus, the growing target patient pool may drive the demand for treatment and promote the sacral nerve stimulation market in the coming years. Furthermore, the rising geriatric population globally is driving the market.
Thus, increasing aging along with growing research investments, and technological advancements associated with the development of novel medical devices are expected to drive the market. However, health risks associated with the devices are expected to slow down the market over the forecast period.
Sacral Nerve Stimulation Market Trends
This section covers the major market trends shaping the Sacral Nerve Stimulation Market according to our research experts:
Sacral Nerve Stimulation in Urinary and Fecal Incontinence Estimated to Witness Growth
The urinary and fecal incontinence segment is estimated to register significant growth in the future, due to the growing prevalence of patients having urinary tract infection (UTI), anal sphincter injuries, and overactive bladders. A research article published in the African Journal of Urology (2021), titled, "Deep insights into urinary tract infections and effective natural remedies" reported that urinary tract infections (UTIs) were the most common outpatient infections. For another instance, in 2021 an article titled, Healthcare-associated urinary tract infections in urology reported that the prevalence of urinary tract infections (UTIs) was significant among the elderly, and the incidence of urinary tract infections (UTIs) in women aged 65 years was high as compared to the total studied population. These populations are expected to create a demand for treatment and thus drive the segment's growth. Moreover, the rising number of people having constipation and pelvic pain is anticipated to boost the segment.
Also, in the American Journal of Obstetrics and Gynecology, 2021, an article titled 'Prevalence and trends in urinary incontinence among women in the United States, 2005-2018', stated that there was a rise in the incidence of various diseases, such as Parkinson's disease, diabetes, and multiple sclerosis, worldwide, which may lead to an increased prevalence of urinary incontinence. This, in turn, is expected to increase the demand for urinary incontinence treatment devices over the forecast period. Furthermore, the growing trend of research and development activities by the key players and the increasing number of product approvals are anticipated to aid in the growth of the segment. For instance, in August 2020, Medtronic's InterStim Micro neurostimulator and InterStim SureScan MRI leads were approved by the United States Food Drug and Administration (USFDA) for the treatment of patients with bladder and bowel control conditions. The InterStim Micro neurostimulator is indicated for the treatment of patients with overactive bladders, fecal incontinence, and non-obstructive urinary retention, through sacral neuromodulation therapy.
Thus, owing to the aforementioned factors, the studied segment is expected to witness significant growth over the forecast period.
North America Expected to Hold a Significant Share in the Market
North America is expected to hold a significant share of the sacral nerve stimulation market due to the rising prevalence of overactive bladder conditions (OAB) and urge incontinence, the growing awareness of the availability of treatment, and the increasing adoption of technologically advanced medical devices, such as implantable sacral nerve stimulation (SNS) devices. Furthermore, the well-established infrastructure, growing healthcare expenditure, and favorable reimbursement policies for these devices and treatment procedures are expected to fuel the market studied in this region. Also, the presence of the major key market players, recent mergers, acquisitions, product launches, and partnerships in the region is driving the market. For instance, in February 2021, Axonics Modulation Technologies Inc. completed the acquisition of the privately-held Contura Ltd. and its flagship product, Bulkamid, which is indicated for the treatment of stress urinary incontinence (SUI) in women. For another instance, in April 2022, the Axonics, F15 device was cleared by the United States Food and Drug Administration (USFDA) allowing it to be implanted for upward of 15 years to block the abnormal nerve signals linked to overactive bladder and fecal incontinence.
The increasing geriatric population and the growing demand for minimally-invasive surgeries also aid in the growth of the studied market in North America. Additionally, as per the article published in February 2021, titled 'Cross-sectional Study of Prevalence and Correlates of Urinary Incontinence (UI) in Older Home-care Clients With Type 2 Diabetes in Ontario, Canada,' among 118,519 older adults with diabetes, 39,945 (33.7%) of them had daily or multiple daily episodes of Urinary Incontinence (UI). Also, as per an article published in Medscape in June 2021, urinary incontinence was estimated to affect 10-13 million people in the United States. Also, the region is marked by a high incidence of diabetes. Diabetes is marked by improper utilization of insulin or lack of insulin by the body cells, resulting in glycosuria. The urinary tract infection (UTI) is one of the most frequent due to the glucose increase in blood circulation and the impairment of cellular immunity, creating a favorable environment for bacteria proliferation at the inflammation spots. Thus, the high incidence of diabetes among the American population is marked by a high incidence of urinary tract infection (UTI), thereby increasing the demand for surgical procedures, and contributing to the market growth.
Thus, the growing burden of urinary incontinence in the region is likely to be one of the major drivers for the studied market over the forecast period.
Sacral Nerve Stimulation Industry Overview
The sacral nerve stimulation market is fragmented in nature due to the presence of fewer companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known as Nuvectra Corporation, Medtronic PLC, NeuroPace Inc., Laborie Inc., Axonics Modulation Technologies Inc., Nevro Corp., Boston Scientific Corporation, Synapse Biomedical Inc., St. Jude Medical Inc.(Abbott Laboratories), Johnson and Johnson, Biomedical Life Systems Inc., Kegel8 (Savantini Limited), EnteroMedics Inc., LivaNova PLC, and Inspire Medical Systems Inc.
Sacral Nerve Stimulation Market Leaders
-
Nuvectra
-
Medtronic
-
NeuroPace, Inc.
-
Laborie, Inc
-
Axonics Modulation Technologies, Inc.
*Disclaimer: Major Players sorted in no particular order
Sacral Nerve Stimulation Market News
- In 2022, Medtronic plc announced it received approval from the United States Food and Drug Administration (USFDA) for InterStim X, the next generation of the InterStim portfolio's recharge-free device. The InterStim system is an advanced therapy option, and the most personalized system, to deliver sacral neuromodulation (SNM) therapy.
- In March 2021, Axonics Modulation Technologies Inc. entered a strategic alliance with Micro Systems Technologies (MST) for the manufacture of a non-rechargeable implantable sacral neuromodulation device.
Sacral Nerve Stimulation Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Prevalence of Overactive Bladder Conditions
- 4.2.2 Increasing Incidence of Urge Incontinence
-
4.3 Market Restraints
- 4.3.1 Health Risks Associated with the Devices
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 By Product
- 5.1.1 External Sacral Nerve Stimulation
- 5.1.2 Implantable Sacral Nerve Stimulation
-
5.2 By Applications
- 5.2.1 Urge Incontinence
- 5.2.2 Urinary and Fecal Incontinence
- 5.2.3 Chronic Anal Fissure
- 5.2.4 Other Applications
-
5.3 By End-Users
- 5.3.1 Hospitals
- 5.3.2 Ambulatory Surgical Centers
- 5.3.3 Other End-Users
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle-East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle-East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Nuvectra Corporation
- 6.1.2 Medtronic PLC
- 6.1.3 NeuroPace Inc.
- 6.1.4 Laborie Inc.
- 6.1.5 Axonics Modulation Technologies Inc.
- 6.1.6 Nevro Corp.
- 6.1.7 Boston Scientific Corporation
- 6.1.8 Synapse Biomedical Inc.
- 6.1.9 St. Jude Medical Inc.(Abbott Laboratories)
- 6.1.10 Johnson and Johnson
- 6.1.11 Biomedical Life Systems Inc.
- 6.1.12 Kegel8 (Savantini Limited)
- 6.1.13 EnteroMedics Inc.
- 6.1.14 LivaNova PLC
- 6.1.15 Inspire Medical Systems Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablitySacral Nerve Stimulation Industry Segmentation
As per the scope of the report, sacral nerve stimulation also referred to as sacral neuromodulation therapy, is a reversible treatment that uses a device to send electrical impulses to sacral nerves that control bladder functions. This treatment is adopted by patients who have fecal and urinary dysfunction. The sacral nerve stimulation market is segmented by Product Type (External Sacral Nerve Stimulation, Implantable Sacral Nerve Stimulation), Application (Urge Incontinence, Urinary, and Fecal Incontinence, Chronic Anal Fissure, and Other Applications), End-Users (Hospitals, Ambulatory Surgical Centers, and Other End-Users), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Product | External Sacral Nerve Stimulation | |
| Implantable Sacral Nerve Stimulation | ||
| By Applications | Urge Incontinence | |
| Urinary and Fecal Incontinence | ||
| Chronic Anal Fissure | ||
| Other Applications | ||
| By End-Users | Hospitals | |
| Ambulatory Surgical Centers | ||
| Other End-Users | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Sacral Nerve Stimulation Market Research FAQs
What is the current Global Sacral Nerve Stimulation Market size?
The Global Sacral Nerve Stimulation Market is projected to register a CAGR of 5.5% during the forecast period (2024-2029)
Who are the key players in Global Sacral Nerve Stimulation Market?
Nuvectra, Medtronic, NeuroPace, Inc., Laborie, Inc and Axonics Modulation Technologies, Inc. are the major companies operating in the Global Sacral Nerve Stimulation Market.
Which is the fastest growing region in Global Sacral Nerve Stimulation Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Sacral Nerve Stimulation Market?
In 2024, the North America accounts for the largest market share in Global Sacral Nerve Stimulation Market.
What years does this Global Sacral Nerve Stimulation Market cover?
The report covers the Global Sacral Nerve Stimulation Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Sacral Nerve Stimulation Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global Sacral Nerve Stimulation Industry Report
Statistics for the 2024 Global Sacral Nerve Stimulation market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. Global Sacral Nerve Stimulation analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
